The booster doses of the vaccine are both shown to induce stronger antibody responses than a single dose, with the standard dose / standard dose inducing the best response – supporting the decision taking previously to move to a two-dose vaccine regimen in the Phase III clinical trials. The paper also shows that many different antibody functions are triggered by the vaccine that may be important in protection from the disease. In the second paper, the authors detail an extensive investigation of the T cell and antibody responses generated by ChAdOx1 nCoV-19. This type of T cell response in combination with the detailed antibody profile is highly favourable for an efficacious vaccine, and further support the profile of this vaccine as a safe vaccine. ‘Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses’: https://www.nature.com/articles/s41591-020-01179-4‘T cell and antibody responses induced by a single dose of ChAdOx1 nCo
